Abeona Therapeutics Inc. (NASDAQ:ABEO) Q3 2023 Results Conference Call November 13, 2023 8:30 AM ET
Company Participants
Greg Gin - Vice President of Investor Relations & Corporate Communications
Vishwas Seshadri - President, CEO and Director
Madhav Vasanthavada - Chief Commercial Officer & Head of Business Development
Joseph Vazzano - Chief Financial Officer
Conference Call Participants
Kristen Kluska - Cantor Fitzgerald
Operator
Greetings, and welcome to the Abeona Therapeutics Third Quarter 2023 Conference Call. [Operator Instructions]. Please note this conference is being recorded.
I will now turn the conference over to your host, Mr. Greg Gin. Sir, you may begin.
Greg Gin
Thank you, Ali. Good morning, everyone. I would like to welcome and thank everyone for joining us on our third quarter 2023 update conference call. The press release announcing the third quarter '23 results is available on our website at www.abeonatherapeutics.com. Before we start, I would like to note that remarks made during today's call may contain projections and forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are based on current expectations and are subject to change, and actual results may differ materially from those expressed or implied in the forward-looking statements.
Various factors that could cause actual results to differ include, but are not limited to, those identified under the Risk Factors section in our Form 10-K and periodic reports filed with the Securities and Exchange Commission. These documents are available on our website at www.abeonatherapeutics.com.
On today's call with prepared remarks are Dr. Vish Seshadri, Chief Executive Officer; Dr. Madhav Vasanthavada, Chief Commercial Officer and Head of Business Development; and Joe Vazzano, Chief Financial Officer. Also joining us for the Q&A session will be Dr. Brian Kevany, Chief Technical Officer.
With that, I will now turn the call over to Vish Seshadri. Go ahead, Vish.
Vishwas Seshadri
Thank you, Greg. Hello, everybody, and thank you for joining us this morning. I'm pleased to update you on our continued progress evolving from a clinical-stage company to one with a significant commercial opportunity. Let me start with the highlight that everyone at Abeona is thrilled about. We achieved perhaps the most meaningful milestone yet in Abeona's history at the end of September with submission to the FDA of our biologics license application, or BLA, for prademagene zamikeracel or pz-cel, which was formerly known as EB-101. Pz-cel is our investigational autologous COL7A1 gene-corrected epidermal sheet or recessive dystrophic epidermolysis bullosa or RDEB.